April 1st, 2021
CrownBio and Innoland Biosciences, Co. Ltd (InnolandBio) have reached agreement for the acquisition of CrownBio’s Cardiovascular and Metabolic Disease (CVMD) business unit.
As part of the agreement, all staff, assets and capabilities based at CrownBio’s Taicang facility have immediately transferred to InnolandBio, minimizing disruption to clients. Studies will be delivered by the same Study Director, the same technical team, under the same protocol, at the same facility.
Please note that the following services will continue to be available with CrownBio:
Our team is here.
If you have any questions please contact:
Yixin (Jim) Wang, PhD